[Dopa-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated hemiparkinsonian monkeys].
Infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) into the right common carotid artery of 5 rhesus monkeys produced hemiparkinsonian syndrome in the contralateral limbs which responded to madopa or apomorphine therapy. Moreover, these two drugs induced circling away from the MPTP-treated side, amphetamine induced rotation toward the MPTP-treated side. Long-term use of madopa developed a peak-dose dyskinesia of the face and the limbs contralateral to the MPTP-treated side. The ipsilateral toxic effects were confirmed biochemically by reduction of nigrostriatal DA and histologically by degeneration of nigral neurons of the MPTP-treated side. It is concluded that this hemiparkinsonian model of rhesus monkey will be of value in the elucidation of the neural mechanism underlying L-DOPA or DA agonist induced dyskinesia in Parkinson's disease and in the search for newer methods of treatment which would produce less dyskinesia and response fluctuations.
Chen
S
S
Department of Neurology, Ren Ji Hospital, Shanghai Second Medical University.
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000662:Amphetamines / Q000009:adverse effects*; D000818:Animals; D001058:Apomorphine / Q000009:adverse effects*; D001545:Benserazide / Q000009:adverse effects*; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors; D004338:Drug Combinations; D004409:Dyskinesia, Drug-Induced / Q000209:etiology*; D005260:Female; D007980:Levodopa / Q000009:adverse effects*; D008253:Macaca mulatta; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000188:drug therapy*
D000662:Amphetamines; D004338:Drug Combinations; C005177:benserazide, levodopa drug combination; D007980:Levodopa; D001545:Benserazide; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D002262:Carboxy-Lyases; D001058:Apomorphine